Use of Whole-Body Periodic Acceleration Therapy To Aches and Pains

Center for Translational Medicine30 enrolled

Overview

The purpose of this study is to test the effectiveness of whole body periodic acceleration for helping with symptoms of aches and pains suffered by many patients.

This is an unblinded cross-over study of whole-body periodic acceleration (WBPA) to ascertain if this treatment modality provides symptomatic relief of pain, stiffness, and abnormal gait and balance in a variety of conditions. The study will compare a specific mechanism of motion, whole-body periodic acceleration (WBPA), that has been shown to increase the release of beneficial mediators from the vascular endothelium into the circulation, to a control condition of slow passive motion that promotes relaxation but does not increase release of beneficial mediators into the circulation. The study tests the efficacy and safety of a commercially available device that consists of a motion platform, called Exer-Rest©, that is capable of producing both types of motion to be tested. In this investigation, 15 subjects will be randomly assigned to either procedure for 10 treatments for 2 weeks followed by a one-week "wash-out" period. Then the opposite treatment will be employed for two weeks.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pain Stiffness Abnormal Gait Balance

Interventions

Whole body periodic acceleration (Exer-Rest)DEVICE

Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Subjects qualifying for this study satisfy the following criteria: 1. Over 18 years of age; 2. Complain of either chronic pain, joint stiffness, and/or dysfunctions of gait and balance; 3. Complaints have been annotated by a competent physician, and the subject has been evaluated for conditions that commonly contribute to the respective symptoms; 4. Capable of completing the appropriate testing and baseline assessments, such as quantitative electroencephalography (qEEG) and questionnaires; 5. Tolerate the motion and duration of treatment of the WBPA. 6. Be available for regular visits to the research site for the duration of the study. Exclusion Criteria: WBPA is contraindicated for subjects who are pregnant or who suffer with unexplained leg pain, skin eruptions, or who have unstable spinal injuries or conditions. Subjects who cannot tolerate the motion and duration of treatment are also excluded.

Locations (1)

Translational Medicine Group

Bethesda, Maryland, United States

RECRUITING

Outcomes

Primary Outcomes

Self-report of pain

Self-report of pain at start and completion of first course of treatment lasting for 2 weeks.

Time frame: 2 weeks

Secondary Outcomes

Quality of life

Self-report of change in quality following 2 weeks of treatment.

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.